Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00790192 · ClinicalTrials.gov registry record · Phase 3
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 study of Schizophrenia, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 488
- Enrollment target
- 20
- Study locations
NCT00790192 is a Phase 3 study of Schizophrenia that has completed, run by Sumitomo Pharma America. The registered enrollment target is 488 participants, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (125% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT00790192, a Phase 3 study of Schizophrenia, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 488 participants
- Enrollment target
- 20
- Study locations
Study Summary
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe as compared with quetiapine XR short term among acutely psychotic patients with chronic schizophrenia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Lurasidone
- DRUG Quetiapine XR
Study Locations (20)
California
- Clinical Pharmacological Studies, Inc. - Cerritos
- Comprehensive Neuroscience, Inc - Cerritos
- Clinical Innovations, Inc. - Costa Mesa
- Synergy Escondido - Escondido
- Collaborative Neuroscience Network - Garden Grove
- Apostle Clinical Trials, Inc. - Long Beach
- California Clinical Trials - Paramount
- Pasadena Research Institute - Pasadena
- CNRI-Los Angeles. LLC - Pico Rivera
- Clinical Innovations, Inc. - Riverside
- CNRI-San Diego - San Diego
- UCSD Medical Center - Sandeigo
Arkansas
- K&S Professional Research Services, LLC - Little Rock
- Woodland International Research Group - Little Rock
Florida
- Florida Clinical Research Center - Bradenton
- Florida Clinical Research Center, LLC - Fruitland Park
Louisiana
- Lake Charles Clinical Trials - Lake Charles
- Booker, J. Gary, MD. APMC - Shreveport
Colorado
- Segal Institute for Clinical Research - Highlands Ranch
District of Columbia
- Comprehensive Neuroscience, Inc. - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 488 participants |
| Start Date | 2008-10 |
| Est. Completion | 2010-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00790192
The ClinicalTrials.gov registry entry for NCT00790192 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 488 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (125% higher). The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00790192 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Arkansas, Florida.
Frequently Asked Questions
What is clinical trial NCT00790192 about?
NCT00790192 is a clinical study titled "Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.". Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe as compared with quetiapine XR short term among acutely psychotic patients with chronic schizophrenia.
What is the current status of trial NCT00790192?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 488 participants. The study started on 2008-10. Estimated completion is 2010-07.
What conditions does trial NCT00790192 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT00790192?
The interventions under investigation include: Placebo (DRUG), Lurasidone (DRUG), Quetiapine XR (DRUG).
Who is sponsoring clinical trial NCT00790192?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00790192 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.